Sarepta Therapeutics (SRPT) Research & Development (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Research & Development of $154.0 million for Q1 2026, down 80.09% year-over-year from $773.4 million in Q1 2025, and down 52.68% quarter-over-quarter from $325.3 million in Q4 2025.
Sarepta Therapeutics (SRPT) Research & Development (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $154.0 million for Q1 2026.
- In Q1 2026, Research & Development fell 80.09% year-over-year to $154.0 million; the TTM figure through Mar 2026 stood at $902.6 million (down 34.48% YoY), while the FY2025 annual figure was $1.5 billion, up 89.19% from the prior year.
- Research & Development for Q1 2026 stood at $154.0 million, down from $325.3 million in the prior quarter.
- The five-year high for Research & Development was $773.4 million in Q1 2025, with the low at $154.0 million in Q1 2026.
- The 5-year median for Research & Development is $213.8 million (2022), against an average of $249.1 million.
- The sharpest annual moves came in 2025 and 2026: Research & Development jumped 285.96% in 2025, then tumbled 80.09% in 2026.
- Sarepta Therapeutics' Research & Development stood at $213.8 million in 2022, then retreated by 8.55% to $195.5 million in 2023, then increased by 2.27% to $200.0 million in 2024, then soared by 62.71% to $325.3 million in 2025, then sank by 52.68% to $154.0 million in 2026.
- Business Quant data shows SRPT's Research & Development at $154.0 million in Q1 2026, $325.3 million in Q4 2025, and $218.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 91.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.26 Mn |
| Mar 31, 2026 | 153.96 Mn |
| Dec 31, 2025 | 325.34 Mn |
| Sep 30, 2025 | 218.89 Mn |
| Jun 30, 2025 | 204.39 Mn |
| Mar 31, 2025 | 773.45 Mn |
| Dec 31, 2024 | 199.95 Mn |
| Sep 30, 2024 | 224.48 Mn |
| Jun 30, 2024 | 179.69 Mn |
| Mar 31, 2024 | 200.40 Mn |
| Dec 31, 2023 | 195.52 Mn |
| Sep 30, 2023 | 194.30 Mn |
| Jun 30, 2023 | 241.89 Mn |
| Mar 31, 2023 | 245.68 Mn |
| Dec 31, 2022 | 213.80 Mn |
| Sep 30, 2022 | 216.71 Mn |
| Jun 30, 2022 | 252.33 Mn |
| Mar 31, 2022 | 194.25 Mn |
| Dec 31, 2021 | 197.30 Mn |
| Sep 30, 2021 | 139.12 Mn |